文献速递角膜与眼表疾病

美国干眼与睑板腺功能障碍的患病率和发病率:系统综述与Meta分析

Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

该系统综述与Meta分析检索Ovid MEDLINE和Embase,纳入2010年1月1日至2021年8月16日发表的13项研究,评估美国干眼与睑板腺功能障碍(MGD)的患病率和发病率。Meta分析估计干眼患病率为8.1%(95%CI 4.9%-13.1%),MGD患病率为21.2%(95%CI 7.2%-48.3%),干眼发病率在18岁及以上人群为3.5%、68岁及以上人群为7.8%,无研究报告MGD发病率。作者结论认为美国干眼与MGD的患病率和发病率存在不确定性,需要采用一致且经过验证的定义开展基于人群的流行病学研究。

要点

  • Meta分析估计美国干眼患病率为8.1%(95%CI 4.9%-13.1%),MGD患病率为21.2%(95%CI 7.2%-48.3%)。
  • 干眼发病率在18岁及以上人群为3.5%,在68岁及以上人群为7.8%。
  • 无研究报告MGD发病率,作者结论认为患病率和发病率存在不确定性。

核心结论

  • 该系统综述与Meta分析表明美国干眼与MGD的患病率和发病率存在不确定性,需要采用一致且经过验证的定义开展基于人群的流行病学研究以获得更高确定性的估计。

研究设计与样本

  • 系统综述与Meta分析,检索Ovid MEDLINE和Embase,检索时间为2021年8月16日,纳入2010年1月1日至2021年8月16日发表的研究,不限参与者年龄和发表语言,排除病例报告、病例系列、病例对照研究和干预性研究。
  • 共纳入13项研究,其中10项报告干眼患病率、2项报告干眼发病率、3项报告MGD患病率。
  • 数据提取由1名评价者完成、另一名评价者核实准确性,采用Joanna Briggs Institute和Newcastle Ottawa Scale工具评估偏倚风险,患病率分别采用随机效应模型进行Meta分析。

主要发现

  • Meta分析估计干眼患病率为8.1%(95%CI 4.9%-13.1%;95%预测区间 0%-98.9%;3项研究;9 808 758名参与者)。
  • Meta分析估计MGD患病率为21.2%(95%CI 7.2%-48.3%;95%预测区间 0%-100%;3项研究;19 648名参与者)。
  • 干眼发病率在18岁及以上人群为3.5%,在68岁及以上人群为7.8%。
  • 无研究报告MGD发病率。

关键数值与推荐

  • 干眼患病率8.1%(95%CI 4.9%-13.1%;95%预测区间 0%-98.9%;3项研究;9 808 758名参与者)。
  • MGD患病率21.2%(95%CI 7.2%-48.3%;95%预测区间 0%-100%;3项研究;19 648名参与者)。
  • 干眼发病率在18岁及以上人群为3.5%,在68岁及以上人群为7.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者结论指出美国干眼与MGD的患病率和发病率存在不确定性。
  • 作者指出需要采用一致且经过验证的干眼与MGD定义开展基于人群的流行病学研究,以获得更高确定性的患病率和发病率估计。
  • 干眼患病率Meta分析的95%预测区间为0%-98.9%,MGD患病率Meta分析的95%预测区间为0%-100%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dry eye is a common clinical manifestation, a leading cause of eye clinic visits, and a significant societal and personal economic burden in the United States. Meibomian gland dysfunction (MGD) is a major cause of evaporative dry eye. OBJECTIVE: To conduct a systematic review and meta-analysis to obtain updated estimates of the prevalence and incidence of dry eye and MGD in the United States. DATA SOURCES: Ovid MEDLINE and Embase. STUDY SELECTION: A search conducted on August 16, 2021, identified studies published between January 1, 2010, and August 16, 2021, with no restrictions regarding participant age or language of publication. Case reports, case series, case-control studies, and interventional studies were excluded. DATA EXTRACTION AND SYNTHESIS: The conduct of review followed a protocol registered on PROSPERO (CRD42021256934). PRISMA guidelines were followed for reporting. Joanna Briggs Institute and Newcastle Ottawa Scale tools were used to assess risk of bias. Data extraction was conducted by 1 reviewer and verified by another for accuracy. Prevalence of dry eye and MGD were combined in separate meta-analyses using random-effects models. MAIN OUTCOMES AND MEASURES: Prevalence and incidence of dry eye and MGD in the United States. Summary estimates from meta-analysis of dry eye and MGD prevalence with 95% CI and 95% prediction intervals (95% PI). RESULTS: Thirteen studies were included in the systematic review. Dry eye prevalence was reported by 10 studies, dry eye incidence by 2 studies, and MGD prevalence by 3 studies. Meta-analysis estimated a dry eye prevalence of 8.1% (95% CI, 4.9%-13.1%; 95% PI, 0%-98.9%; 3 studies; 9 808 758 participants) and MGD prevalence of 21.2% (95% CI, 7.2%-48.3%; 95% PI, 0%-100%; 3 studies; 19 648 participants). Dry eye incidence was 3.5% in a population 18 years and older and 7.8% in a population aged 68 years and older. No studies reported MGD incidence. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis demonstrated uncertainty about the prevalence and incidence of dry eye and MGD in the United States. Population-based epidemiological studies that use consistent and validated definitions of dry eye and MGD are needed for higher-certainty estimates of dry eye and MGD prevalence and incidence in the United States.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. McCann P, Abraham AG, Mukhopadhyay A, et al. Prevalence and Incidence of Dry Eye and Meibomian Gland Dysfunction in the United States: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022. PMID: 36301551. doi:10.1001/jamaophthalmol.2022.4394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。